Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.
Saved in:
| Title: | Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial. |
|---|---|
| Authors: | Szepietowski JC; Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland., Reich A; Department of Dermatology, Medical College of Rzeszów University, Rzeszów, Poland., Feldman SR; Department of Dermatology, Pathology, and Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA., Pulka G; Department of Dermatology, Centrum Medyczne All-Med Badania Kliniczne, Kraków, Poland., Mekokishvili L; Petre Shotadze Tbilisi Medical Academy, School of Medicine, Tbilisi, Georgia., Tsiskarishvili N; Department of Rheumatology, Georgian-American University, Tbilisi, Georgia., Svarca I; Department of Dermatology, Health and Aesthetics LTD, Riga, Latvia., Poder A; Department of Dermatology, Kliiniliste Uuringute Keskus OU, Tartu Linn, Estonia., Singh G; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Deodhar S; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Kumar K; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Marwah A; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Loganathan S; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Wolff-Holz E; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India., Athalye SN; Department of Clinical Development, Salarpuria Senorita, Bengaluru, India. |
| Source: | Expert opinion on biological therapy [Expert Opin Biol Ther] 2025 Oct; Vol. 25 (10), pp. 1121-1133. Date of Electronic Publication: 2025 Oct 21. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Comparative Study; Multicenter Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41100115 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Szepietowski+JC%22">Szepietowski JC</searchLink>; Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland.<br /><searchLink fieldCode="AU" term="%22Reich+A%22">Reich A</searchLink>; Department of Dermatology, Medical College of Rzeszów University, Rzeszów, Poland.<br /><searchLink fieldCode="AU" term="%22Feldman+SR%22">Feldman SR</searchLink>; Department of Dermatology, Pathology, and Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA.<br /><searchLink fieldCode="AU" term="%22Pulka+G%22">Pulka G</searchLink>; Department of Dermatology, Centrum Medyczne All-Med Badania Kliniczne, Kraków, Poland.<br /><searchLink fieldCode="AU" term="%22Mekokishvili+L%22">Mekokishvili L</searchLink>; Petre Shotadze Tbilisi Medical Academy, School of Medicine, Tbilisi, Georgia.<br /><searchLink fieldCode="AU" term="%22Tsiskarishvili+N%22">Tsiskarishvili N</searchLink>; Department of Rheumatology, Georgian-American University, Tbilisi, Georgia.<br /><searchLink fieldCode="AU" term="%22Svarca+I%22">Svarca I</searchLink>; Department of Dermatology, Health and Aesthetics LTD, Riga, Latvia.<br /><searchLink fieldCode="AU" term="%22Poder+A%22">Poder A</searchLink>; Department of Dermatology, Kliiniliste Uuringute Keskus OU, Tartu Linn, Estonia.<br /><searchLink fieldCode="AU" term="%22Singh+G%22">Singh G</searchLink>; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India.<br /><searchLink fieldCode="AU" term="%22Deodhar+S%22">Deodhar S</searchLink>; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India.<br /><searchLink fieldCode="AU" term="%22Kumar+K%22">Kumar K</searchLink>; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India.<br /><searchLink fieldCode="AU" term="%22Marwah+A%22">Marwah A</searchLink>; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India.<br /><searchLink fieldCode="AU" term="%22Loganathan+S%22">Loganathan S</searchLink>; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India.<br /><searchLink fieldCode="AU" term="%22Wolff-Holz+E%22">Wolff-Holz E</searchLink>; Clinical Development and Medical Affairs, Biocon Biologics Limited, Bengaluru, India.<br /><searchLink fieldCode="AU" term="%22Athalye+SN%22">Athalye SN</searchLink>; Department of Clinical Development, Salarpuria Senorita, Bengaluru, India. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101125414%22">Expert opinion on biological therapy</searchLink> [Expert Opin Biol Ther] 2025 Oct; Vol. 25 (10), pp. 1121-1133. <i>Date of Electronic Publication: </i>2025 Oct 21. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Comparative Study; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101125414 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-7682 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214712598%22">14712598 </searchLink><i>NLM ISO Abbreviation: </i>Expert Opin Biol Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41100115 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/14712598.2025.2576506 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1121 Titles: – TitleFull: Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Szepietowski JC – PersonEntity: Name: NameFull: Reich A – PersonEntity: Name: NameFull: Feldman SR – PersonEntity: Name: NameFull: Pulka G – PersonEntity: Name: NameFull: Mekokishvili L – PersonEntity: Name: NameFull: Tsiskarishvili N – PersonEntity: Name: NameFull: Svarca I – PersonEntity: Name: NameFull: Poder A – PersonEntity: Name: NameFull: Singh G – PersonEntity: Name: NameFull: Deodhar S – PersonEntity: Name: NameFull: Kumar K – PersonEntity: Name: NameFull: Marwah A – PersonEntity: Name: NameFull: Loganathan S – PersonEntity: Name: NameFull: Wolff-Holz E – PersonEntity: Name: NameFull: Athalye SN IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2025 Oct Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1744-7682 Numbering: – Type: volume Value: 25 – Type: issue Value: 10 Titles: – TitleFull: Expert opinion on biological therapy Type: main |
| ResultId | 1 |
